Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sarissa Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This prosecution activity is handled by 1 distinct examiner and is situated within 1 distinct art unit. The presence of 1 pending office action in the Biotechnology & Pharmaceuticals sector indicates a focused stage of prosecution. The company is likely pursuing protection for a specific core technology, as evidenced by the lack of multiple active matters across different art units.
The busiest examiner for this portfolio is BELL, SARA ELIZABETH, who is responsible for 1 busiest examiner pending office action. Given that the total pending office actions for the Biotechnology & Pharmaceuticals filings is 1, this examiner is the only official currently engaged with the company's pending matters. This focus means that the immediate outcomes for the portfolio are tied to the feedback from this 1 examiner. Practitioners must tailor their arguments to the concerns of BELL, SARA ELIZABETH, as there are no other active cases in the 1 distinct art unit to provide alternative pathways.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270624 | RAD51 BINDING INHIBITORS AND METHODS OF USE THEREOF | BELL, SARA ELIZABETH | 132d overdue |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270624 | RAD51 BINDING INHIBITORS AND METHODS OF USE THEREOF | BELL, SARA ELIZABETH | 1625 | §112 | Final Rejection | 132d overdue | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial